Investors sold shares of Juno Therapeutics Inc (NASDAQ:JUNO) on strength during trading on Friday. $23.76 million flowed into the stock on the tick-up and $36.57 million flowed out of the stock on the tick-down, for a money net flow of $12.81 million out of the stock. Of all stocks tracked, Juno Therapeutics had the 0th highest net out-flow for the day. Juno Therapeutics traded up $0.41 for the day and closed at $29.21

Several research firms recently commented on JUNO. Leerink Swann restated an “outperform” rating and issued a $60.00 price target on shares of Juno Therapeutics in a research note on Friday, July 8th. Cowen and Company began coverage on shares of Juno Therapeutics in a research note on Thursday, May 5th. They issued an “outperform” rating and a $55.00 price target on the stock. Zacks Investment Research downgraded shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. Barclays PLC initiated coverage on shares of Juno Therapeutics in a research note on Wednesday, July 6th. They issued an “equal weight” rating and a $48.00 price target on the stock. Finally, FBR & Co reaffirmed a “buy” rating on shares of Juno Therapeutics in a research report on Saturday, July 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $53.11.

The company’s market capitalization is $2.96 billion. The company has a 50-day moving average price of $40.01 and a 200-day moving average price of $38.03.

Juno Therapeutics (NASDAQ:JUNO) last released its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.78) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.52) by $0.26. The firm earned $9.80 million during the quarter, compared to the consensus estimate of $4.83 million. During the same quarter last year, the firm earned ($0.30) EPS. Equities analysts forecast that Juno Therapeutics Inc will post ($2.28) EPS for the current fiscal year.

In related news, CEO Hans Edgar Bishop sold 90,750 shares of Juno Therapeutics stock in a transaction dated Thursday, June 9th. The stock was sold at an average price of $46.42, for a total value of $4,212,615.00. Following the completion of the sale, the chief executive officer now owns 2,704,609 shares of the company’s stock, valued at approximately $125,547,949.78. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, General Counsel Bernard J. Cassidy sold 3,116 shares of Juno Therapeutics stock in a transaction dated Thursday, May 19th. The stock was sold at an average price of $39.03, for a total value of $121,617.48. Following the completion of the sale, the general counsel now directly owns 55,511 shares of the company’s stock, valued at approximately $2,166,594.33. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors recently bought and sold shares of the stock. BNP Paribas Arbitrage SA raised its position in Juno Therapeutics by 27.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 51,206 shares of the biopharmaceutical company’s stock worth $2,252,000 after buying an additional 10,884 shares during the last quarter. US Bancorp DE raised its position in Juno Therapeutics by 1.8% in the fourth quarter. US Bancorp DE now owns 88,700 shares of the biopharmaceutical company’s stock worth $3,900,000 after buying an additional 1,600 shares during the last quarter. BBR Partners LLC bought a new position in Juno Therapeutics during the fourth quarter worth $1,539,000. Baillie Gifford & Co. bought a new position in Juno Therapeutics during the fourth quarter worth $12,312,000. Finally, Stevens Capital Management LP bought a new position in Juno Therapeutics during the fourth quarter worth $2,315,000.

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Juno’s product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.